Vacunas contra el virus dengue: desarrollo histórico.

Vaccines against dengue virus: History.

Alicia Aguilar, Nevis Amin, Ela María Pérez

Instituto Finlay. Centro de Investigación Producción de Vacunas y Sueros. Ciudad de La Habana, Cuba. E-mail: elaperez@finlay.edu.cu

RESUMEN

La Fiebre del Dengue (FD) y la Fiebre Hemorrágica del Dengue (FHD) han emergido como la principal enfermedad viral transmitida por artrópodos que afecta al hombre. Las características de la enfermedad, la ausencia de drogas antivirales contra la misma, el incremento en el número de enfermos, de países afectados y la dificultad para el control del vector han convertido el desarrollo de vacunas contra el dengue en una prioridad para la salud pública mundial. Los intentos para lograr este objetivo datan de mediados del siglo pasado para lo cual han sido exploradas diferentes estrategias. A pesar de los avances realizados al respecto mucho queda por aclarar y definir para disponer de un inmunógeno contra el virus.

Palabras claves: dengue, vacuna

Dengue Fever (DF) and Dengue Haemorragic Fever (DHF) have emerged as the most important human viral diseases transmitted by arthropod vectors. The characteristics of this disease, plus the absence of effective antiviral drugs, the increase in the number of cases, affected countries and the difficulties for vector control have made the development of dengue vaccines a public health priority. Since the middle of the past century many strategies have been explored to achieve this objective. In spite of the advances in this field, there is much research to be done in order to have available an immunogen against dengue.

Keywords: dengue, vaccine.

Texto completo formato PDF

REFERENCIAS

1. Henchal EA, Putnak JR. The dengue viruses. Clin microb Rev. 1990; 3(4):376-396.

2. Pancharoen C, Kulwichit W,Tantawichien T, Thisyakorn U, Thisyakorn C. Dengue infection: a global concern. J Med Assoc Thai. 2002; 85:25-7.

3. Kourí GP, Guzmán MG, Bravo JR, Triana C. Dengue Hemorrhagic Fever/ Dengue Shock syndrome: lessons from the Cuban epidemic, 1981. Bull WHO. 1989; 67: 375- 380.

4. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V y cols. Risk factors in dengue shock syndrome: a prospective epidemiological study in Rayong, Thailand I: the 1980 outbreak. Am J Epidemiol. 1984; 120:653-669.

5. Halstead SB. Pathogenesis of Dengue: challenge to Molecular Biology. Science. 1988; 239:476-481.

6. Kurane I, Rothman Al, Livingston PE, Green S, Gagnon SJ, Janus J, Innis BL, Nimmannitya S, Nisalak A, Ennis FA. Immunopathologic mechanisms of dengue hemorrhagic fever and dengue shock syndrome. Arch Virol. 1994; Suppl 9:59-64.

7. Rico-Hesse R, Harrison LM, Salas RA, et al. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology. 1997; 230:244-251.

8. Gubler DJ, Clark GC. Dengue/Dengue Hemorrhagic Fever: the emergence of a global health problem. Emerg Inf Dis.1995; 1(2):55-57.

9. Rigau-Pérez J, Clark G,Gubler DJ, Reiter P, Sanders EJ, Vorndam V. Dengue and dengue haemorrhagic fever. Lancet 1998; 352:971-977.

10. Guzmán MG. Avances para la obtención de una vacuna contra el dengue. Acta Científica Venezolana. 1998; 49(Supl 1):38-45.

11. Brandt WE. Current approches to the development of Dengue vaccines and related aspects of the molecular biology of flaviviruses. J Inf Dis. 1988; 157(5):1105-1111-126.

12. Barret AD. Current status of flavivirus vaccines. Ann N Y Acad Sci. 2001; 951:262-271.

13. Innis, BL. Dengue and Dengue Hemorrhagic Fever. En: Exotic Infections. Porterfield. Chapman and Hall London. 1995:103-146.

14. Bielefeldt - Ohmann H. Obstacle to the development of Dengue virus vaccines: enhancement of disease by neutralizing antiviral antibodies and virus evolution? Vaccine Res. 1997; 6(3 ):113

15. Sabin AB. Recent advances in our knowledge of Dengue and Sandfly fever. Am J Trop Med Hyg. 1955; 4:198: 207.

16. Schlesinger RW, Gordon I, Frankiel JM, Winter JM, Patterson PR, Dorrance WE. Clinical and serological responses of man to immunization with attenuated Dengue and Yellow Fever virus. J Immunol. 1956; 77: 352- 364.

17. Wisseman CL, Sweet BH, Rosenzweig EC, Eylar OR. Attenuated living type 1 Dengue vaccines. Am J Trop Med Hyg. 1963; 12:620:623.

18. Sabin AB, Schlesinger RW. Production of immunity to Dengue virus with virus modified by propagation in mice. Science. 1945; 101:640- 642.

19. Eckels KH, Harrison VR, Summers PL, Russell PK. Dengue 2 vaccine: Preparation from a small virus clone. Inf Immun. 1980; 27:175-180.

20. Halstead SB, Diwan AR, Marchette NJ, Palumbo NE, Srisukonth L. Selection of an attenuated Dengue 4 viruses by serial passage in primary kidney cells. I. Attributes of uncloned virus at different passages levels. Am J Trop Med Hyg. 1984; 33 (4):654-655.

21. Bancroft WH, Top FH, Eckels KH, Anderson JH Jr., Mc Cown JM, Rusell PK. Dengue - 2 vaccine: virological, immunological, and clinical responses of six Yellow fever immune recipients. Inf Immun. 1981; 31:678-703.

22. Bancroft WH, Scott R McN, Eckels KH, Hoke JH Jr., Simms TE, Jesrani KD, Summers PL, Dubois DR, Tsoulos D, Rusell PK. Dengue type 2 vaccine: reactogenicity and immunogenicity in soldiers. J Infect Dis. 1984; 149:1005- 1010.

23. Eckels KH, Scott R McN, Bancroft WH, Brown J, Dubois DR, Summers PL, Rusell PK, Halstead SB. Selection of an attenuated Dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in foetal rhesus lung cells. Am J Trop Med Hyg. 1984; 33(4):684- 689.

24. Mckee KT Jr, Bancroft WH, Eckels KH, Redfield RR, Summers PL, Rusell PK. Lack of attenuation of a candidate dengue 1 vaccine (45 AZ5) in human voluntareers. Am J Trop Med Hyg. 1987; 36(2):435-442.

25. Innis BL, Eckels KH, Kraiselburd E, Dubois DR, Meadors GF, Gubler DJ, Burke DS, Bancroft WH. Virulence of a live vaccine candidate: a possible new marker of Dengue virus attenuation. J Infect Dis. 1988; 158:876-880.

26. Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Eckels KH, Dubois DR, Summers PL, Hoke CH. A live attenuated Dengue - 1 vaccine candidate ( 45 AZ5 ) passaged in Primary Kidney Dog Cell Culture is atenuatted and immunogenic for humans. J Infect Dis. 1994; 170:1448-1455.

27. Marchette NJ, Dubois DR, Larsen LK, Summers PL, Kraiselburd EG, Gubler DJ, Eckels KH. Preparation of an attenuated Dengue 4 ( 341750 ) virus vaccine. I. Preclinical studies. Am J Trop Med Hyg. 1990;43 (2): 219-226.

28. Hoke cH, Malinoski FJ, Eckels KHH, Scott RM, Dubois DR, Summer PL, Simms Tt, Burrous J, Hasty SE, Bancroft WH. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II Safety and immunogenicity in humans. AM J Trop Med Hyg. 1990; 43(2):219-226.

29. Bhamarapravati, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine. 2000; 18(Supp 2):44-47.

30. Alvarez M, Guzmán MG, Pupo M, Morier L, Bravo J and Rodriguez R. Study of biologic attributes of Cuban dengue 2 virus after serial pasaje in primary dog kidney cells. Int J Infect Dis.2001; 5(1):35-39.

31. Ada G, Ramsay A. Traditional - type human vaccines and vaccination practices. En: Vaccine, vaccination and the immune response. Filadelfia, New York: Lippincott - Raven Publishers. 1996:12-36.